Premium
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients
Author(s) -
TEITEL J.,
BERNTORP E.,
DOLAN G.,
FISCHER K.,
GRINGERI A.,
KESSLER C.,
LAMBERT T.,
LEISSINGER C.,
NEMES L.,
SHIMA M.
Publication year - 2011
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2010.02440.x
Subject(s) - medicine , haemophilia , clinical trial , statement (logic) , standardization , haemophilia a , alternative medicine , medline , intensive care medicine , family medicine , pediatrics , pathology , political science , law
Summary. The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom